Clinical trial · Interventional
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma
Yt90Zevalin Plus CHOP, Z-CHOP
NCT00386321CI-TRIAL-00004120terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Participants are no longer being examined or treated.
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the treatment of Yt90 Zevalin in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)are effective as first line treatment in patients with bulky stage II or stage III or IV diffuse large B-cell lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 2-year progression-free survival and overall survival of patients
Secondary outcomes (2)
- measure
- Response rate (partial response, complete unconfirmed response, and complete response)in patients
- measure
- 2-year progression-free survival, overall survival and response rate in BCL-2 positive patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed CD20 positive diffuse large B-cell lymphoma with bulky stage II or stage III or stage IV * Bidimensionally measurable disease * Performance status Zubrod 0-2 * Less than 20,000/mcL circulating lymphoid cells on WBC differential count * No clinical evidence of CNS involvement, no prior diagnosis of indolent lymphoma, no histologic transformation * Ejection fraction more than or equal to 45% by MUGA or no significant abnormality by echocardiogram * Fertile patients with effective contraception method * No other malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer, stage I or II cancer in complete remission, or carcinoma in situ of cervix * No HIV positive, no prior solid organ transplantation * No prior antibody therapy, chemotherapy, radiotherapy for lymphoma Exclusion Criteria: * Serum creatinine ot bilirubin more than 2.5 X ULN unless due to lymphoma * Active uncontrolled infection * Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study * Patients with more than 25% infiltrated bone marrow * Patients with platelet counts less than 100,000/mcL or neutrophil counts less than 1,500/mcL
References
Publications (0)
Data not yet available
No reference posted for this study.